State Ledger
Company profile

Apimeds Pharmaceuticals US, Inc. CIK 1894525

Ticker
APUS (NYSE)
Industry
Pharmaceutical Preparations
Headquarters
Matawan, NJ 07747
Fiscal year end
2025 (FY)
Market Data
Close
$4.65
Change
-$0.78
Change %
-14.38%
Volume
7,841

APUS · trading date Oct 9, 2026 · previous close $5.43 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$6.00M
Total assets
$164.18M
Total liabilities
$10.84M
Stockholders' equity
$153.35M
Cash & equivalents
$1.64M
Operating income
-$11.91M
Operating cash flow
-$8.93M
Capital expenditures
$57.3K

Fiscal year 2025, via 10-K filed 2026-05-04. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$8.98M
Free cash flow margin
—
Liabilities / assets
6.6%
Equity / assets
93.4%
CapEx / revenue
—
Operating cash flow / net income
1.49×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$6.00M $164.18M $10.84M $153.35M
2024 — -$1.39M $13.1K $1.37M -$1.36M
2023 — -$777.7K $422.1K $390.2K $31.9K
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 8-K
2026-09-11
Financials filed via
Form 10-K
filed 2026-05-04

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Matawan, NJ 07747
100 MATAWAN RD
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:40 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to New Jersey — Public Companies